Tumor necrosis factor inhibitor drugs market to reach $48.58 billion by 2030 at 2.8% CAGR, driven by increasing prevalence of autoimmune disorders worldwide.
Read More
Tumor models market to reach $3.57 billion by 2030 at 10.8% CAGR, driven by growing demand for personalized medicine and tailored cancer treatment testing.
Read More
Tumor infiltrating lymphocytes market to reach $23.25 billion by 2030 at 14.0% CAGR, driven by rising number of cancer patients increasing demand for immunotherapies.
Read More
Tubulin inhibitors for breast cancer market to reach $2.78 billion by 2030 at 7.4% CAGR, driven by growing prevalence of chronic diseases including breast cancer.
Read More
Tuberous sclerosis drug market to reach $1.26 billion by 2030 at 8.1% CAGR, driven by rising incidence of chronic diseases requiring long term disease management.
Read More
Tuberculous meningitis treatment market to reach $307.93 billion by 2030 at 10.3% CAGR, driven by growing prevalence of meningitis and rising healthcare expenditure.
Read More
Trispecific antibodies market to reach $1.66 billion by 2030 at 16.2% CAGR, driven by rising demand for targeted therapies enabled by precision medicine advances.
Read More
Trial size supplements market to reach $4.2 billion by 2030 at 10.4% CAGR, driven by rising demand for health and wellness products and increasing disposable incomes.
Read More
Treprostinil sodium market to reach $1.97 billion by 2030 at 9.4% CAGR, driven by increasing cases of pulmonary diseases linked to pollution and aging populations.
Read More
Travel vaccines market to reach $8.16 billion by 2030 at 10.0% CAGR, driven by increasing travel and tourism boosting demand for preventive immunization solutions.
Read More